查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103678

類澱粉沉積症治療市場：全球市場預測（2026-2032 年）

Amyloidosis Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，類澱粉沉積症治療市場將成長至 102.1 億美元，複合年成長率為 7.56%。

主要市場統計數據
基準年（2025 年） 61.3億美元
預計年份（2026年） 65.9億美元
預測年份（2032年） 102.1億美元
複合年成長率（） 7.56%

類澱粉沉積症治療：執行摘要

隨著人們對澱粉樣變性疾病的認知不斷提高，基於生物標記的診斷、基因檢測以及器官特異性治療方案的出現，類澱粉沉積症的治療正進入一個臨床動態發展階段，這正在重塑全身性和局部性澱粉樣變性患者的治療方式。類澱粉沉積症是一組罕見的蛋白質退化性疾病，其特徵是不溶性澱粉樣蛋白纖維在心臟、腎臟、肝臟、胃腸道和周圍神經等器官中積聚。整體情況很大程度取決於澱粉樣蛋白的類型，包括免疫球蛋白輕鏈類澱粉沉積症、轉甲狀腺素蛋白澱粉樣類澱粉沉積症、A型澱粉樣蛋白類澱粉沉積症、透析相關性類澱粉沉積症變性和遺傳變異型。在輕鏈類澱粉沉積症中，治療的重點是抑制異常漿細胞的活性，以防止不可逆的神經病變。對於轉甲狀腺素類澱粉沉積症，已批准使用轉甲狀腺素蛋白穩定劑、基因靜默療法以及心肌病和多發性神經病變的支持療法。

類澱粉沉積症治療前景的變革性變化

類澱粉沉積症變性治療格局正在經歷一場變革，這得益於早期診斷、疾病修正治療以及從症狀管理到標靶干預的轉變。傳統上，許多患者只有在心臟、腎臟或神經系統功能嚴重受損後才被診斷出來。目前的臨床實踐正在推動對高風險族群進行系統性篩檢。這些族群包括有不明原因的保留血小板功能性心臟衰竭家族病史、心臟衰竭室壁增厚、雙側腕隧道症候群、脊椎狹窄、肱二頭肌腱斷裂、自主神經病變、蛋白尿、單克隆丙種球蛋白血症和轉甲狀腺素蛋白基因突變的患者。這種早期診斷工作尤其重要，因為器官反應和存活率與在嚴重功能衰退發生前開始治療密切相關。

人工智慧對類澱粉沉積症治療的累積影響

人工智慧 (AI) 正透過增強診斷懷疑、加速影像學結果解讀、支持風險分層以及提高臨床工作流程效率，開始影響類澱粉沉積症的治療。由於類澱粉沉積症通常表現為非特異性症狀，AI 驅動的模式識別可以幫助臨床醫生從電子健康記錄病歷、實驗室檢查結果、心電圖、心臟超音波圖報告、心臟磁振造影、保險理賠數據和長期用藥史中識別預警訊號。這些工具在轉甲狀腺素類澱粉沉積症樣變性心臟疾病中特別有用，該疾病在老年患者中，尤其是有心臟衰竭、傳導異常、主動脈瓣狹窄、低電壓心電圖模式、心室壁增厚或腕管症候群病史的患者中，診斷延遲仍然是一個臨床難題。

類澱粉沉積症治療的區域分析

在亞太地區，隨著先進醫療服務的普及、先進心臟影像的可及性提高，以及在快速老化國家中人們對遺傳性和老齡化轉甲狀腺素類澱粉沉積症樣變性的認知不斷增強，類澱粉沉積症的治療格局正在改變。日本在轉甲狀腺素蛋白疾病（包括神經系統和心臟表現）的臨床治療方面擁有悠久的歷史，而中國、印度、韓國和澳洲則加強了罕見疾病基礎設施建設、專家轉診網路以及基因檢測的普及。然而，在基於質譜的澱粉樣蛋白分型、核醫閃爍顯像和疾病修正治療的可及性方面，主要大都會圈與二級醫療機構之間仍然存在差距。

關於類澱粉沉積症治療的主要群體考量因素

在東協地區，類澱粉沉積症治療的進展受到心血管和腎臟疾病篩檢力度加大、私部門專科醫療服務擴張以及部分成員國逐步納入罕見疾病政策等因素的影響。然而，醫療資源的可近性仍然不均衡，先進的診斷方法和疾病修正治療主要集中在高所得的都市區。因此，加強醫生培訓、提升檢查室能力以及建立跨區域轉診途徑對於改善輕鏈類澱粉沉積症、轉甲狀腺素類澱粉沉積症和遺傳性澱粉樣變性疾病的診斷至關重要。

各國類澱粉沉積症治療情形分析。

美國在多學科類澱粉沉積症計畫的臨床實施、廣泛的專家參與、先進的影像技術以及基於生物標記的監測的廣泛應用方面發揮了主導作用。另一方面，加拿大則強調透過學術機構、省級醫療保健系統以及罕見疾病轉診途徑協作式醫療。在墨西哥，由於循環系統和血液學領域的專業知識不斷拓展，人們對類澱粉沉積症的認知正在提高，但先進的診斷服務仍集中在主要城市。在巴西，在主要都市區專科醫療中心的支持下，澱粉樣變性心肌病和漿細胞疾病方面的專業知識正在不斷積累，但更廣泛的醫療服務獲取取決於當地的醫療保健系統、公共醫療保險覆蓋範圍以及澱粉樣蛋白類型鑑定的普及程度。

為類澱粉沉積症治療領域的領導者提供的實用建議

行業領導者應優先考慮能夠縮短診斷時間、提高澱粉樣變性亞型確診率以及幫助患者獲得相應專科護理的解決方案。最具可行性的途徑在於支持循環系統、腎臟病學、神經病學、病理學和血液學實踐中基於實證醫學的診斷流程。當懷疑類澱粉沉積症的原因包括不明原因的心臟衰竭、心室壁增厚、蛋白尿、腎病綜合症、神經神經病變、單克隆蛋白觀察、雙側腕管症候群或家族病史，這種支持尤為重要。教育計畫應重點關注實用的轉診標準、血清遊離輕鏈檢測和免疫固定電泳結果的解讀、心臟閃爍顯像在特定患者中的作用、遺傳諮詢的要求，以及在確診轉甲狀腺素蛋白性心臟疾病之前排除輕鏈類澱粉沉積症樣變性的重要性。

分析方法

本報告基於結構化的二級研究途徑，該方法以檢驗的臨床、監管、流行病學和醫療保健系統證據為基礎。此分析方法強調同行評審的醫學文獻、臨床實踐指南、監管文件、罕見疾病政策文件、衛生部門公告以及經認可的醫學和科研機構發布的數據。資訊來源的可靠性、及時性、分析方法品質以及與類澱粉沉積症變性治療（包括輕鏈類澱粉沉積症、轉甲狀腺素類澱粉沉積症樣變性、遺傳性澱粉樣變性、澱粉樣變性心肌病病變、腎類澱粉沉積症樣變性、澱粉樣變性類澱粉沉積症和系統性發炎性類澱粉沉積症樣變性）的相關神經病變進行評估。

結論

類澱粉沉積症的治療正從分散的、高階管理轉向更早期、更精準、多學科的綜合治療。這項進展得益於診斷工具的改進、對澱粉樣變性心肌病和神經病變的認知提高、基因檢測的廣泛應用、基於生物標記的監測以及針對主要澱粉樣變性疾病修正治療。儘管取得了這些進展，但診斷延遲、澱粉樣變性分型機會不均、專科醫生短缺以及保險報銷差異等問題仍然影響著患者的治療結果，且不受地域限制。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章類澱粉沉積症治療市場：依治療類型分類

  • 藥物治療
    • 烷化劑
    • 免疫調節劑
    • 單株抗體
    • 蛋白酶體抑制劑
      • Bortezomib
      • Carfilzomib
      • 伊沙佐米
    • TTR消音器
      • 伊諾特森
      • 糕點師
    • TTR穩定器
      • 阿科拉米迪斯
      • 塔法米迪斯
  • 幹細胞移植
  • 支持性護理

第8章類澱粉沉積症治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第9章類澱粉沉積症治療市場：依類澱粉沉積症類型分類

  • 遺傳性ATTR
  • 野生型 ATTR

第10章：類澱粉沉積症治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第11章類澱粉沉積症治療市場：依治療方法分類

  • 疾病修正治療
  • 症狀管理療法
  • 澱粉樣蛋白減少療法

第12章類澱粉沉積症治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章類澱粉沉積症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章類澱粉沉積症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第16章：公司簡介

  • AbbVie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Attralus Inc.
  • BridgeBio Pharma Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics Inc.
  • CRISPR Therapeutics AG
  • CSL Vifor
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline plc
  • Intellia Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Johnson & Johnson Services Inc.
  • Merck KGaA
  • Neurimmune AG
  • Novartis AG
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation plc
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Silence Therapeutics plc
  • Som Biotech SL
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Inc.
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market is projected to grow by USD 10.21 billion at a CAGR of 7.56% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.13 billion
Estimated Year [2026] USD 6.59 billion
Forecast Year [2032] USD 10.21 billion
CAGR (%) 7.56%

Amyloidosis Treatment Executive Summary

Amyloidosis treatment is entering a clinically dynamic phase as improved disease recognition, biomarker-led diagnosis, genetic testing, and organ-specific care pathways reshape how patients with systemic and localized amyloid disorders are managed. Amyloidosis refers to a group of rare, protein-misfolding diseases in which insoluble amyloid fibrils accumulate in organs such as the heart, kidneys, liver, gastrointestinal tract, and peripheral nerves. The treatment landscape is primarily influenced by amyloid type, including immunoglobulin light chain amyloidosis, transthyretin amyloidosis, amyloid A amyloidosis, dialysis-related amyloidosis, and hereditary variants. For light chain amyloidosis, therapy focuses on suppressing abnormal plasma cell activity and preventing irreversible organ damage. For transthyretin amyloidosis, approved approaches include transthyretin stabilizers, gene-silencing therapies, and supportive management for cardiomyopathy and polyneuropathy.

The clinical need remains substantial because delayed diagnosis is common, symptoms often overlap with heart failure, chronic kidney disease, neuropathy, and inflammatory disorders, and advanced organ involvement limits therapeutic reversibility. Evidence-based care increasingly depends on multidisciplinary coordination across hematology, cardiology, nephrology, neurology, pathology, nuclear medicine, and genetic counseling. In parallel, greater use of cardiac imaging, serum free light chain testing, immunofixation, cardiac biomarkers, mass spectrometry-based amyloid typing, and noninvasive bone scintigraphy for selected transthyretin cardiac cases is improving diagnostic accuracy. These shifts are expanding the role of precision medicine in amyloidosis treatment while emphasizing early intervention, longitudinal monitoring, and patient-centered management.

Transformative Shifts in the Amyloidosis Treatment Landscape

The amyloidosis treatment landscape is being transformed by earlier diagnosis, disease-modifying therapies, and a shift from symptom control toward targeted intervention. Historically, many patients were diagnosed only after advanced cardiac, renal, or neurologic impairment. Current clinical practice is moving toward structured screening in high-risk populations, including individuals with unexplained heart failure with preserved ejection fraction, increased ventricular wall thickness, bilateral carpal tunnel syndrome, spinal stenosis, biceps tendon rupture, autonomic neuropathy, proteinuria, monoclonal gammopathy, and family history of transthyretin variants. This earlier diagnostic orientation is particularly important because organ response and survival outcomes are strongly linked to treatment initiation before severe functional decline.

Therapeutic innovation is also changing care priorities. In light chain amyloidosis, plasma cell-directed regimens adapted from hematologic malignancy treatment are increasingly combined with rigorous organ response monitoring and supportive cardiac and renal care. In transthyretin amyloidosis, stabilizing and gene-silencing strategies are shifting treatment from palliation to disease modification, while emerging approaches targeting amyloid depletion, fibril clearance, and next-generation genetic medicines continue to attract clinical attention. At the same time, treatment delivery is being shaped by real-world challenges, including access to specialized diagnostic tools, reimbursement complexity, rare disease referral gaps, and the need for centers experienced in amyloid typing. The most important competitive differentiator for healthcare stakeholders is no longer a single therapeutic modality but the ability to integrate diagnosis, subtype confirmation, treatment selection, and long-term monitoring into a coordinated care model.

Cumulative Impact of Artificial Intelligence on Amyloidosis Care

Artificial intelligence is beginning to influence amyloidosis treatment by strengthening diagnostic suspicion, accelerating imaging interpretation, supporting risk stratification, and enabling more efficient clinical workflows. Because amyloidosis often presents with nonspecific symptoms, AI-enabled pattern recognition can assist clinicians in identifying red flags across electronic health records, laboratory trends, electrocardiograms, echocardiography reports, cardiac magnetic resonance imaging, claims data, and longitudinal medication histories. These tools are especially relevant for transthyretin cardiac amyloidosis, where delayed recognition among older adults with heart failure, conduction abnormalities, aortic stenosis, low-voltage electrocardiographic patterns, increased ventricular wall thickness, or carpal tunnel history remains a documented clinical concern.

AI also has cumulative impact across research and treatment development. Machine learning can improve patient identification for rare disease trials, refine phenotyping by integrating cardiac biomarkers, renal parameters, neuropathy measures, and imaging features, and support real-world evidence generation after therapy initiation. In pathology and proteomics, computational tools can assist amyloid detection and classification when used alongside validated laboratory methods, although expert confirmation remains essential. Importantly, AI adoption in amyloidosis care must be governed by data quality, algorithm transparency, clinical validation, privacy safeguards, and bias mitigation. Its greatest near-term value lies not in replacing specialist judgment but in reducing diagnostic delays, standardizing referral triggers, and helping multidisciplinary teams prioritize patients who require amyloid-specific evaluation.

Key Regional Insights Across Amyloidosis Treatment

In Asia-Pacific, amyloidosis treatment is shaped by expanding tertiary care capacity, growing access to advanced cardiac imaging, and increasing awareness of hereditary and age-related transthyretin amyloidosis in countries with rapidly aging populations. Japan has longstanding clinical experience in transthyretin disease, including neurologic and cardiac manifestations, while China, India, South Korea, and Australia are strengthening rare disease infrastructure, specialist referral networks, and access to genetic testing. However, availability of mass spectrometry-based amyloid typing, nuclear scintigraphy, and disease-modifying therapies remains uneven between major metropolitan centers and secondary-care settings.

North America demonstrates strong uptake of multidisciplinary amyloidosis programs, broad use of cardiac scintigraphy and biomarker monitoring, and high clinical trial activity across light chain and transthyretin amyloidosis. The United States and Canada benefit from established rare disease advocacy networks, advanced laboratory capabilities, genetic counseling services, and academic referral pathways, but diagnostic delay persists due to symptom overlap with more common cardiovascular, renal, and neurologic disorders.

Latin America is progressing through improved specialist awareness, expanding hematology and cardiology capabilities, and increasing recognition of amyloid cardiomyopathy in aging populations. Brazil and Mexico are central to regional development, with major urban hospitals supporting advanced diagnosis and specialist-led care. Access to amyloid typing, genetic testing, cardiac magnetic resonance imaging, scintigraphy, and disease-modifying therapies varies by public and private healthcare coverage, reinforcing the importance of practical referral protocols and clinician education.

Europe is characterized by structured referral systems, national rare disease strategies, and strong expertise in amyloid diagnostics, including mass spectrometry, nuclear imaging, cardiac magnetic resonance, and hereditary disease counseling. Countries within the region have advanced clinical networks for both light chain and transthyretin amyloidosis, supported by guideline-based care and specialist centers, though reimbursement timelines, health technology assessment outcomes, and access criteria differ across health systems.

The Middle East is seeing rising investment in specialty care, genetic medicine, and advanced cardiology services, particularly in high-income health systems. Consanguinity patterns in parts of the region increase the importance of genetic counseling and hereditary disease evaluation, while access to highly specialized amyloidosis centers remains concentrated in major urban hospitals. Standardized diagnostic algorithms can further support earlier recognition of cardiac, renal, and neurologic amyloidosis across the region.

Africa faces the greatest diagnostic and treatment access constraints, with limited availability of amyloid typing, advanced imaging, genetic testing, and rare disease-focused infrastructure in many settings. However, regional improvements in nephrology, cardiology, pathology, and genomic medicine are gradually creating opportunities for earlier recognition, particularly in urban referral centers, academic hospitals, and cross-border specialist collaborations.

Key Group Insights Across Amyloidosis Treatment

Across ASEAN, amyloidosis treatment development is influenced by increasing cardiovascular and renal disease screening, expanding private-sector specialty care, and the gradual integration of rare disease policies in selected member states. Access remains heterogeneous, with advanced diagnostics and disease-modifying therapies more concentrated in higher-income urban centers. As a result, physician education, laboratory capacity, and regional referral pathways are critical for improving diagnosis of light chain amyloidosis, transthyretin amyloidosis, and hereditary amyloid disorders.

The GCC is advancing amyloidosis care through investment in tertiary hospitals, genetic testing capacity, digital health infrastructure, and specialty cardiology and hematology services. The region's emphasis on precision medicine supports better hereditary amyloidosis recognition, while centralized health systems can facilitate earlier referral if standardized diagnostic algorithms are widely adopted. Greater integration of genetic counseling, family screening, and cardiac imaging protocols can strengthen care for patients with transthyretin variants and amyloid cardiomyopathy.

The European Union benefits from rare disease frameworks, cross-border reference networks, and regulatory pathways that support orphan medicines and clinical evidence generation. These structures strengthen amyloidosis diagnosis and treatment access by improving referral coordination, data sharing, and specialist collaboration. However, country-level reimbursement procedures, health technology assessments, and local implementation of clinical guidelines can affect the timing and consistency of patient access.

Within BRICS, amyloidosis treatment is shaped by large patient populations, uneven diagnostic access, and growing investment in advanced medical infrastructure. China, India, Brazil, Russia, and South Africa present diverse care environments, but all share the need for scalable screening strategies, local clinician training, and improved access to subtype-confirming diagnostics such as immunofixation, serum free light chain assays, tissue typing, nuclear imaging, and genetic testing.

G7 countries generally have stronger availability of specialist centers, clinical research participation, advanced imaging, molecular diagnostics, and evidence-based multidisciplinary care, enabling more comprehensive management of light chain and transthyretin amyloidosis. However, even in high-resource systems, delayed diagnosis remains a consistent challenge, reinforcing the need for primary care, cardiology, nephrology, hematology, and neurology awareness, especially for patients with unexplained heart failure, proteinuria, neuropathy, or monoclonal protein findings.

NATO member states include many health systems with mature rare disease capabilities and advanced cardiovascular care, but treatment access and diagnostic pathways vary widely across members. Harmonizing referral criteria, improving data sharing within ethical and regulatory limits, and strengthening military and veteran health system awareness may support earlier identification of amyloid cardiomyopathy and neuropathy in relevant populations, particularly where symptoms overlap with age-related cardiovascular or neurologic conditions.

Key Country Insights Across Amyloidosis Treatment

The United States leads in clinical adoption of multidisciplinary amyloidosis programs, broad specialist engagement, advanced imaging, and extensive use of biomarker-based monitoring, while Canada emphasizes coordinated care through academic centers, provincial health systems, and rare disease referral pathways. Mexico is improving recognition of amyloidosis through expanding cardiology and hematology expertise, although advanced diagnostic access remains concentrated in large cities. Brazil has growing expertise in amyloid cardiomyopathy and plasma cell disorders, supported by major urban specialty centers, while broader access depends on regional healthcare capacity, public coverage pathways, and availability of amyloid typing.

The United Kingdom has established specialist amyloidosis services and strong diagnostic expertise, particularly in amyloid typing, cardiac assessment, and organ response monitoring. Germany combines advanced cardiology, hematology, pathology, and nuclear medicine infrastructure with increasing recognition of transthyretin cardiomyopathy. France benefits from structured rare disease networks and specialist referral pathways, while Italy and Spain have active clinical expertise in cardiac and hereditary amyloidosis, supported by growing use of noninvasive diagnostic techniques. Russia has advanced specialty centers in major cities, though geographic scale can affect timely access to diagnosis, genetic counseling, and longitudinal management.

China is rapidly expanding rare disease policies, cardiovascular imaging capacity, and access to genetic testing, making it increasingly important in amyloidosis diagnosis and care model development. India faces a dual challenge of large unmet need and uneven access to advanced diagnostics, but major tertiary hospitals are improving recognition of light chain and transthyretin amyloidosis. Japan has deep experience with hereditary transthyretin amyloidosis and advanced management of cardiac and neurologic presentations, supported by specialist expertise and genetic evaluation. Australia benefits from specialized referral centers, genomic medicine capabilities, and rare disease coordination, while South Korea is strengthening precision diagnostics and specialist-led treatment pathways through advanced hospital networks.

Actionable Recommendations for Amyloidosis Treatment Leaders

Industry leaders should prioritize solutions that shorten the diagnostic journey, improve amyloid subtype confirmation, and connect patients with appropriate specialist care. The most actionable opportunity is to support evidence-based diagnostic algorithms for cardiology, nephrology, neurology, pathology, and hematology settings, especially where unexplained heart failure, increased ventricular wall thickness, proteinuria, nephrotic syndrome, neuropathy, monoclonal protein findings, bilateral carpal tunnel syndrome, or family history raise suspicion of amyloidosis. Education programs should focus on practical referral triggers, interpretation of serum free light chain testing and immunofixation, the role of cardiac scintigraphy in selected patients, genetic counseling requirements, and the importance of ruling out light chain amyloidosis before confirming transthyretin cardiac disease.

Stakeholders should invest in real-world evidence systems that capture diagnostic timelines, organ response, treatment persistence, safety outcomes, hospitalization patterns, functional status, and patient-reported quality of life. Partnerships with specialty centers can strengthen care pathway design, while digital decision support can improve early identification if clinically validated and embedded responsibly into workflows. Access strategies should be tailored to regional health system realities, including reimbursement requirements, diagnostic infrastructure, and availability of multidisciplinary expertise. For sustainable impact, industry leaders should align therapeutic innovation with patient navigation, laboratory capacity, clinician education, genetic counseling, and equitable access initiatives that address both high-resource and underserved settings.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified clinical, regulatory, epidemiological, and healthcare system evidence. The methodology emphasizes peer-reviewed medical literature, clinical practice guidelines, regulatory documentation, rare disease policy resources, health authority communications, and published data from recognized medical and scientific institutions. Sources are assessed for credibility, recency, methodological quality, and relevance to amyloidosis treatment, including light chain amyloidosis, transthyretin amyloidosis, hereditary forms, amyloid cardiomyopathy, renal amyloidosis, amyloid neuropathy, and systemic inflammatory amyloidosis.

The research process synthesizes information across disease biology, diagnostic pathways, therapeutic modalities, regional healthcare access, specialist infrastructure, and emerging technology adoption. Particular attention is given to evidence supporting early diagnosis, amyloid subtype confirmation, multidisciplinary management, biomarker monitoring, imaging use, genetic testing, organ response assessment, and patient outcomes. To maintain analytical integrity, this summary avoids unsupported claims, market sizing, market share analysis, and forecasts. The findings are presented as qualitative, data-backed insights intended to support strategic understanding of the amyloidosis treatment environment without implying quantitative market estimates.

Conclusion

Amyloidosis treatment is advancing from fragmented, late-stage management toward earlier, more precise, and multidisciplinary care. Progress is being driven by improved diagnostic tools, greater recognition of amyloid cardiomyopathy and neuropathy, increased use of genetic testing, biomarker-based monitoring, and disease-modifying therapies for key amyloid subtypes. Despite these advances, delayed diagnosis, unequal access to amyloid typing, limited specialist availability, and reimbursement variability continue to affect patient outcomes across regions.

The next phase of progress will depend on integrating clinical education, validated AI-supported screening, specialist referral networks, real-world evidence, and equitable access strategies. Healthcare stakeholders that align innovation with practical diagnostic pathways and patient-centered care coordination will be best positioned to improve outcomes in light chain amyloidosis, transthyretin amyloidosis, and related systemic amyloid disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Amyloidosis Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Pharmacological Treatment
    • 7.2.1. Alkylating Agents
    • 7.2.2. Immunomodulators
    • 7.2.3. Monoclonal Antibodies
    • 7.2.4. Proteasome Inhibitors
      • 7.2.4.1. Bortezomib
      • 7.2.4.2. Carfilzomib
      • 7.2.4.3. Ixazomib
    • 7.2.5. TTR Silencers
      • 7.2.5.1. Inotersen
      • 7.2.5.2. Patisiran
    • 7.2.6. TTR Stabilizers
      • 7.2.6.1. Acoramidis
      • 7.2.6.2. Tafamidis
  • 7.3. Stem Cell Transplantation
  • 7.4. Supportive Therapy

8. Amyloidosis Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Amyloidosis Treatment Market, by Amyloidosis Type

  • 9.1. Introduction
  • 9.2. Hereditary ATTR
  • 9.3. Wild-Type ATTR

10. Amyloidosis Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Home Care
  • 10.3. Hospital
  • 10.4. Specialty Clinic

11. Amyloidosis Treatment Market, by Therapy Modality

  • 11.1. Introduction
  • 11.2. Disease Modifying Therapy
  • 11.3. Symptom Management Therapy
  • 11.4. Amyloid Reduction Therapy

12. Amyloidosis Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Amyloidosis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Amyloidosis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Alnylam Pharmaceuticals Inc.
  • 16.3. Amgen Inc.
  • 16.4. Arcturus Therapeutics Holdings Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Attralus Inc.
  • 16.7. BridgeBio Pharma Inc.
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Corino Therapeutics Inc.
  • 16.10. CRISPR Therapeutics AG
  • 16.11. CSL Vifor
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Genmab A/S
  • 16.14. GlaxoSmithKline plc
  • 16.15. Intellia Therapeutics Inc.
  • 16.16. Ionis Pharmaceuticals Inc.
  • 16.17. Johnson & Johnson Services Inc.
  • 16.18. Merck KGaA
  • 16.19. Neurimmune AG
  • 16.20. Novartis AG
  • 16.21. Pfizer Inc.
  • 16.22. Proclara Biosciences Inc.
  • 16.23. Prothena Corporation plc
  • 16.24. Regeneron Pharmaceuticals Inc.
  • 16.25. Sanofi SA
  • 16.26. Silence Therapeutics plc
  • 16.27. Som Biotech SL
  • 16.28. Takeda Pharmaceutical Company Limited
  • 16.29. Vertex Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BORTEZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BORTEZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BORTEZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARFILZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARFILZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARFILZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IXAZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IXAZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IXAZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TTR SILENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TTR SILENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TTR SILENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INOTERSEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INOTERSEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INOTERSEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PATISIRAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATISIRAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PATISIRAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TTR STABILIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TTR STABILIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TTR STABILIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACORAMIDIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACORAMIDIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACORAMIDIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TAFAMIDIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TAFAMIDIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TAFAMIDIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELL TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY ATTR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY ATTR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY ATTR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WILD-TYPE ATTR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WILD-TYPE ATTR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WILD-TYPE ATTR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DISEASE MODIFYING THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DISEASE MODIFYING THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DISEASE MODIFYING THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYMPTOM MANAGEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYMPTOM MANAGEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYMPTOM MANAGEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMYLOID REDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYLOID REDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AMYLOID REDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 164. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 194. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 204. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA AMYLOIDOSIS T